Placeholder Banner

BIO Files Amicus Brief Supporting Rehearing of Case Addressing Patent Rights and America Invents Act (AIA) at the U.S. Court of Appeals for the Federal Circuit

July 14, 2017

BIO filed an amicus brief in support of a petition to rehear Helsinn Healthcare S.A. v. TEVA Pharmaceuticals USA, Inc., TEVA Pharmaceutical Industries Ltd. at the U.S. Court of Appeals for the Federal Circuit.

Because modern biotechnological products commonly involve lengthy, resource- and investment-intensive development periods, BIO members depend heavily on robust patent rights and a fair system for adjudicating their validity. Accordingly, it’s important to have certainty regarding the types of transactions and what must be publicly disclosed about those transactions to qualify as invalidating activities under the on-sale bar of the America Invents Act (AIA).

Related Resources
2016-1284, -1787 The Biotechnology Innovation Organization (BIO) As Amicus Curiae Supporting Rehearing En Banc
BIO Brief supporting rehearing en banc in Helsinn v. Teva Phamaceuticals
Discover More
BIO filed an amicus brief in the Supreme Court of the State of California, encouraging its review of the lower court decision in the Gilead Tenofovir Cases.The Court of Appeal decision operates from a misunderstanding of the drug development and FDA…
The Biotechnology Innovation Organization (“BIO”) respectfully moves the Court for leave to file an amicus brief in support of Plaintiffs’ response in opposition to the Defendants’ cross-motion for summary judgment. Copies of the proposed brief and…
BIO filed an amicus brief in a continuing effort to challenge courts' decisions that undermine FDA authority and hinder patient access to medications.The brief was filed in the Supreme Court of the United States (SCOTUS), following the August 2023…